Insmed reported $438.74M in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
BioMarin Pharmaceutical USD 1.66B 870.84M Jun/2026
Cytokinetics USD 181.43M 17.76M Jun/2026
DBV Technologies USD 54.3M 2.5M Jun/2026
Gilead Sciences USD 11.02B 1.54B Jun/2026
Heron Therapeutics USD 92.14M 1.63M Jun/2026
Insmed USD 438.74M 77.74M Jun/2026
Novartis USD 31.37B 4.1B Mar/2026
Regeneron Pharmaceuticals USD 5.53B 422.9M Jun/2026
Sarepta Therapeutics USD 502.91M 3.74M Jun/2026
Ultragenyx Pharmaceutical USD 351M 26M Jun/2026
Vertex Pharmaceuticals USD 3.94B 57.3M Jun/2026